Tag: price-increases
-
U.S. lawmakers press Mylan on EpiPen price increases
Two senior lawmakers on the U.S. Senate’s Judiciary Committee on Monday pushed for information regarding sharp price increases for EpiPens, drug-filled injectable devices used by people to counter potentially deadly allergic reactions. Senator Chuck Grassley, chairman of the Senate Judiciary Committee, wrote Mylan Chief Executive Heather Bresch on Monday to ask how Mylan determined the…
-
Pfizer boosts cancer drug roster with $14 billion Medivation deal
Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.4 percent at $34.84. The offer is a 55-percent premium to Sanofi SA's initial bid to buy Medivation for $52.50 per share in April, which pushed…
-
Exclusive: Makers took big price increases on widely used U.S. drugs
By Caroline Humer NEW YORK (Reuters) – Major drug companies took hefty price increases in the U.S., in some cases more than doubling listed charges, for widely used medications over the past five years, a Reuters analysis of proprietary data found. Together, the price increases on drugs for arthritis, high cholesterol, asthma and other common…
-
In Wisconsin, Trump looks to put rough week behind him
By Steve Holland MILWAUKEE (Reuters) – Donald Trump is fighting to put a difficult week behind him and finish strong on Tuesday in Wisconsin, a state whose primary contest may prove to be a turning point in the race for the Republican presidential nomination. The Republican front-runner is at risk of losing the Midwestern state…
-
Valeant CEO Pearson to return effective immediately, results delayed
By Caroline Humer NEW YORK (Reuters) – Valeant Pharmaceuticals International said on Sunday that Chief Executive Officer Michael Pearson would return from medical leave effective immediately, and it postponed the release of fourth-quarter results planned for Monday. Valeant was under pressure for its drug price increases when it said in late December that Pearson had…